DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...
The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.
Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...
Discover how lightweight, stateless Thin Clients with read-only OS architectures support compliance, extend hardware lifespan ...
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid ...
RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...
Endpoint management has become more challenging for IT teams as organisations adopt remote work, cloud services, and a wider ...
Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.
Investing.com -- DBV Technologies stock surged 30% after the company announced positive results from its Phase III VITESSE clinical trial for VIASKIN Peanut, a treatment for peanut allergies in ...
Clinical Trials Arena on MSN
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial
AstraZeneca’s combination therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) has failed to meet ...
Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results